Inhibition of Hsp90 has been explored in the last years for the potential treatment of a variety of cancers [50,55,56], including CLL, where the Hsp90 inhibitors NVP-AUY922-AG and SNX-7081 have been shown to inhibit AKT and NFκB, and to act synergistically with fludarabine [45,46,57]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.